| Literature DB >> 35058578 |
Mark D Peterson1,2, Michelle A Meade3,4, Paul Lin4, Neil Kamdar4,5,6,7, Gianna Rodriguez3, James S Krause8, Elham Mahmoudi4,9.
Abstract
STUDYEntities:
Mesh:
Year: 2022 PMID: 35058578 PMCID: PMC8828667 DOI: 10.1038/s41393-021-00731-4
Source DB: PubMed Journal: Spinal Cord ISSN: 1362-4393 Impact factor: 2.473
Figure 1.Flow chart of subject inclusion and exclusion for final case and control cohorts.
Descriptive characteristics among adults with SCI (case) or without SCI (control).
| Spinal Cord Injury |
|
|
|---|---|---|
|
| 9081 (100%) | 1474232 (100%) |
|
| ||
| | 10.8 (3.4) | 8.5 (3.2) |
| | 10.3 (8.0–13.0) | 7.6 (6.0–10.3) |
|
| ||
| | 6.0 (1.7) | 5.3 (1.5) |
| | 5.6 (4.7–7.0) | 4.7 (4.2–5.8) |
|
| ||
| | 1384 (15.2%) | 542106 (36.8%) |
| | 2547 (28.0%) | 512676 (34.8%) |
| | 5150 (56.7%) | 419450 (28.5%) |
|
| ||
| | 5252 (57.8%) | 774282 (52.5%) |
| | 3829 (42.2%) | 699950 (47.5%) |
|
| ||
| | 263 (2.9%) | 56134 (3.8%) |
| | 637 (7.0%) | 117545 (8.0%) |
| | 718 (7.9%) | 129689 (8.8%) |
| | 1758 (19.4%) | 285255 (19.3%) |
| | 5705 (62.8%) | 885609 (60.1%) |
|
| ||
| | 58 (0.6%) | 8418 (0.6%) |
| | 2386 (26.3%) | 354512 (24.0%) |
| | 4999 (55.0%) | 784246 (53.2%) |
| | 1451 (16.0%) | 284927 (19.3%) |
| | 187 (2.1%) | 42129 (2.9%) |
|
| ||
| | 1554 (17.1%) | 250582 (17.0%) |
| | 1479 (16.3%) | 222644 (15.1%) |
| | 1622 (17.9%) | 258445 (17.5%) |
| | 886 (9.8%) | 151485 (10.3%) |
| | 1376 (15.2%) | 245106 (16.6%) |
| | 2164 (23.8%) | 345970 (23.5%) |
All adults with SCI have their Index Date set the same as start of eligibility date (start of 2007, year when turned 18, or enrollment start date, whichever was the latest)
Incidence of any and all psychological morbidities among adults with and without SCI with one-year clean enrollment period.
| Spinal Cord Injury |
| |
|---|---|---|
|
|
| |
|
| 1292/8532 (15.1%) | 105424/1433868 (7.4%) |
|
| 654/8836 (7.4%) | 62556/1450761 (4.3%) |
|
| 2006/7851 (25.6%) | 200415/1382550 (14.5%) |
| | 147/9031 (1.6%) | 8306/1470937 (0.6%) |
|
| 1403/8385 (16.7%) | 49250/1457864 (3.4%) |
| | 756/8895 (8.5%) | 25981/1468871 (1.8%) |
|
| 19/9073 (0.2%) | 1612/1473687 (0.1%) |
|
| 2075/7368 (28.2%) | 171236/1363578 (12.6%) |
|
| 83/9048 (0.9%) | 4717/1472497 (0.3%) |
|
| 465/8777 (5.3%) | 33513/1463413 (2.3%) |
|
| 896/8773 (10.2%) | 58915/1464738 (4.0%) |
P<.01 and standard mean difference (SMD) ≥0.2
Denominators for both cases and controls reflect a one-year clean period during their enrollment for the specific condition. For instance, among cases (SCI), there exist 8,532 patients whose first year of enrollment had no evidence of insomnia; therefore, inferred incident insomnia could be estimated for this subset of the full SCI cohort. As a result, all patient cohorts’ denominators dynamically change conditional on the incident outcome being measured to ensure a clean period in the first year of enrollment
Figure 2.Disease-free survival and Kaplan-Meier product-limit survival curves (3-year) for adults with SCI (blue) and without SCI (red), for any psychological morbidity.
Survival models with parametric Weibull regression was completed stepwise for each incident psychological outcome to examine the effects of incremental adjustment on the exposure variable (SCI).
| Psychological Morbidities |
|
|
|
|
|---|---|---|---|---|
|
| 2.14 (2.02, 2.26) | 1.74 (1.64, 1.83) | 1.42 (1.34, 1.50) | 1.41 (1.33, 1.49) |
|
| 1.73 (1.60, 1.87) | 2.04 (1.88, 2.20) | 1.77 (1.64, 1.92) | 1.75 (1.62, 1.89) |
|
| 1.84 (1.76, 1.92) | 1.79 (1.71, 1.88) | 1.48 (1.41, 1.55) | 1.47 (1.41, 1.54) |
|
| 2.84 (2.41, 3.36) | 3.42 (2.89, 4.05) | 2.52 (2.13, 2.98) | 2.50 (2.11, 2.96) |
|
| 5.07 (4.79, 5.37) | 2.34 (2.21, 2.48) | 1.96 (1.85, 2.07) | 1.94 (1.84, 2.05) |
|
| 4.86 (4.50, 5.24) | 1.80 (1.67, 1.94) | 1.53 (1.42, 1.64) | 1.52 (1.41, 1.64) |
|
| 1.92 (1.22, 3.02)** | 2.29 (1.45, 3.61) | 1.55 (0.98, 2.46) | 1.55 (0.98, 2.44) |
|
| 2.41 (2.31, 2.52) | 2.12 (2.03, 2.22) | 1.69 (1.62, 1.77) | 1.69 (1.61, 1.77) |
|
| 2.81 (2.25, 3.50) | 3.19 (2.55, 3.98) | 2.05 (1.64, 2.57) | 2.04 (1.63, 2.55) |
|
| 1.74 (1.56, 1.93) | 1.83 (1.64, 2.03) | 1.52 (1.36, 1.69) | 1.51 (1.36, 1.68) |
|
| 2.51 (2.35, 2.69) | 2.32 (2.17, 2.49) | 1.68 (1.57, 1.80) | 1.69 (1.58, 1.81) |
Model 1: Unadjusted
Model 2: Model 1 + Demographic variables (age, sex, race, geographic region).
Model 3: Model 1 + Model 2 + Modified Elixhauser Comorbidity Index
Model 4: Model 1 + Model 2 + Model 3 + Education + Net Worth
As with incidence estimates (Table 2), all survival models used cases (SCI) and control cohorts consistent with Table 2, which required a one-year clean period with no evidence of the condition being measured
P-value < 0.001